Creso Pharma (ASX:CPH) is now selling in South Africa, after commercial partner Pharma Dynamics successfully launched cannaQIX®Regular under the brand name Cannamics in the country.
“We are very excited that Pharma Dynamics managed such a great launch of cannaQIX®Regular, Cannamics in South Africa, providing a strong basis to enter further countries in Africa,” said Creso cofounder and CEO Dr Miri Halperin Wernli.
Pharma Dynamics, a subsidiary of Lupin Limited (NSE:LUPIN), is one of South Africa’s leading pharmaceutical companies and its fifth biggest generic pharmaceutical company.
Creso says Pharma Dynamics is well-known for its investments into innovative wellness programs towards holistic healthcare. Its over-the-counter product range includes cold and flu medications, and allergy, heartburn and immune booster treatments.
It also has a prescription portfolio with cardiovascular and central nervous system products that are prescribed and recommended by leading doctors and pharmacists throughout South Africa.
“In spite of COVID-19 lockdown we managed to launch Cannamics, which brings recognised benefits in these difficult times. We are excited to enter this new category with such a renowned partner in the CBD space,” said Pharma Dynamics business development head Tommy Scott.
Cannamics is glucose-free and contains no tetrahydrocannabinol (THC).
Creso says the standardised strength and formulation allows precise dosage control and the pastilles have a more palatable taste compared to oils.
Cannamics has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso Pharma’s partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG.
This story was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing. This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
June 9, 2020